ArticleVirchows Archiv : an international journal of pathology2013
Ki-67 is a reliable pathological grading marker for neuroendocrine tumors.
Article in Virchows Archiv : an international journal of pathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 64 citations in OpenAlex.
- Renal Neuroendocrine Tumor Mimicking Upper Tract Urothelial Carcinoma.IJU case reports · 2026Article
- Incidence and characterization of spontaneous pituitary neuroendocrine tumors in aged spontaneously hypertensive rats.Scientific reports · 2025Article
- The Genomic Topography of Appendiceal Cancers: Our Current Understanding, Clinical Perspectives, and Future Directions.Cancers · 2025Review
- Article
- Multimodal imaging findings of primary renal well-differentiated neuroendocrine tumors (carcinoid): a case report and literature review.Frontiers in oncology · 2025Article
- Endoscopic Ultrasound-Guided Diagnosis of Gallbladder Mixed Neuroendocrine Non-Neuroendocrine Tumor With an Anomalous Pancreaticobiliary Junction.ACG case reports journal · 2024Article
- Predictors of Outcomes in Gastric Neuroendocrine Tumors: A Retrospective Cohort.GE Portuguese journal of gastroenterology · 2024Article
- Surgical Management and Long-Term Evaluation of Pancreatic Neuroendocrine Tumors.The Surgical clinics of North America · 2024Review
- Liver-Directed Locoregional Therapies for Neuroendocrine Liver Metastases: Recent Advances and Management.Current oncology (Toronto, Ont.) · 2024Review
- High Ki67 Gene Expression Is Associated With Aggressive Phenotype in Hepatocellular Carcinoma.World journal of oncology · 2024Article
- Primary Well-Differentiated Neuroendocrine Tumor of the Kidney.Journal of kidney cancer and VHL · 2023Article
- EMT Molecular Signatures of Pancreatic Neuroendocrine Neoplasms.International journal of molecular sciences · 2022Article
- Primary Breast Neuroendocrine Tumors: An Analysis of the National Cancer Database.Annals of surgical oncology · 2022Article
- The Potential and Emerging Role of Quantitative Imaging Biomarkers for Cancer Characterization.Cancers · 2022Review
- Clinicopathologic profile of gastroenteropancreatic neuroendocrine neoplasms in a referral center of South India.International journal of clinical and experimental pathology · 2022Article
- Review
- Review
- Mutational analysis of extranodal marginal zone lymphoma using next generation sequencing.Oncology letters · 2020Article
- Hypothesis-free deep survival learning applied to the tumour microenvironment in gastric cancer.The journal of pathology. Clinical research · 2020Article
- Generative Adversarial Domain Adaptation for Nucleus Quantification in Images of Tissue Immunohistochemically Stained for Ki-67.JCO clinical cancer informatics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In neuroendocrine tumors (NETs), proliferation markers, especially Ki-67, have become increasingly important. This study was designed to examine the reproducibility of Ki-67 for use in the current classification of NETs. A retrospectively assembled integrated database with prospectively collected data of patients undergoing multidisciplinary management for NETs from 2000 to 2009 was analyzed. Original pathology was reviewed to reassess Ki-67 values. Ki-67 was then categorized to grades G1 (≤2 %), G2 (3-20 %), or G3 (>20 %) according to the European Neuroendocrine Tumor Society (ENETS) guidelines and the 2010 World Health Organization (WHO) classification. Original Ki-67 values were compared to reviewed values. All statistical analyses were carried out using SAS 9.1.3. A total of 184 patients were included of which 48 % were male. The most common primary NET site was the small bowel, in 27 %. On pathology review, there was 94 % agreement for G1, with 4 % of cases upgraded at review to G2 and 2 % of cases upgraded to G3. For G2, there was 94 % agreement, with 6 % of cases downgraded to G1 and 0 % upgraded. For G3, there was 90 % agreement, with 10 % of cases downgraded to G2 and none to G1 (kappa = 0.89). Ki-67 is a proliferative marker for NETs that is highly reproducible when used to grade tumors according to ENETS and WHO categories. The high inter-institutional reliability in the determination of tumor grade as assessed by Ki-67 makes it a reliable tool in the assessment of patients with NETs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.